AUROBINDO PHARMA
|
AUROBINDO PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 54.16 | 32.90 | 45.20 | 91.05 | 48.56 |
| CEPS(Rs) | 80.06 | 54.14 | 64.41 | 109.05 | 65.03 |
| DPS(Rs) | 4.50 | 3.00 | 9.00 | 4.00 | 3.00 |
| Book NAV/Share(Rs) | 509.35 | 458.10 | 419.46 | 374.29 | 287.16 |
| Tax Rate(%) | 27.65 | 26.21 | 21.51 | 27.37 | 24.03 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.77 | 7.31 | 9.17 | 10.98 | 10.29 |
| EBIT Margin(%) | 7.81 | 5.41 | 7.16 | 15.27 | 8.57 |
| Pre Tax Margin(%) | 7.33 | 5.14 | 7.05 | 15.11 | 7.92 |
| PAT Margin (%) | 5.30 | 3.79 | 5.54 | 10.98 | 6.02 |
| Cash Profit Margin (%) | 7.85 | 6.24 | 7.89 | 13.15 | 8.06 |
| Performance Ratios | |||||
| ROA(%) | 7.63 | 5.29 | 7.90 | 17.16 | 10.33 |
| ROE(%) | 11.18 | 7.50 | 11.38 | 27.53 | 18.52 |
| ROCE(%) | 13.76 | 9.39 | 12.71 | 30.10 | 18.72 |
| Asset Turnover(x) | 1.44 | 1.40 | 1.43 | 1.56 | 1.72 |
| Sales/Fixed Asset(x) | 2.84 | 2.95 | 3.24 | 3.73 | 4.12 |
| Working Capital/Sales(x) | 5.17 | 5.10 | 4.84 | 5.35 | 9.40 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.35 | 0.34 | 0.31 | 0.27 | 0.24 |
| Receivable days | 28.34 | 30.42 | 28.69 | 29.37 | 29.85 |
| Inventory Days | 55.92 | 57.65 | 63.29 | 62.82 | 57.72 |
| Payable days | 133.88 | 117.74 | 108.60 | 111.03 | 107.32 |
| Valuation Parameters | |||||
| PER(x) | 20.12 | 15.75 | 14.80 | 9.68 | 8.51 |
| PCE(x) | 13.61 | 9.57 | 10.39 | 8.08 | 6.35 |
| Price/Book(x) | 2.14 | 1.13 | 1.59 | 2.36 | 1.44 |
| Yield(%) | 0.41 | 0.58 | 1.35 | 0.45 | 0.73 |
| EV/Net Sales(x) | 2.20 | 1.17 | 1.59 | 2.06 | 1.17 |
| EV/Core EBITDA(x) | 9.98 | 7.26 | 7.94 | 8.95 | 5.32 |
| EV/EBIT(x) | 13.68 | 10.58 | 10.92 | 6.90 | 6.65 |
| EV/CE(x) | 1.77 | 0.92 | 1.11 | 1.53 | 0.94 |
| M Cap / Sales | 2.20 | 1.22 | 1.67 | 2.08 | 1.05 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.68 | 5.97 | -5.32 | 7.26 | 18.07 |
| Core EBITDA Growth(%) | 59.64 | -14.83 | -17.62 | 13.02 | 23.10 |
| EBIT Growth(%) | 69.62 | -19.54 | -53.88 | 83.25 | 20.80 |
| PAT Growth(%) | 64.40 | -27.18 | -50.37 | 87.57 | 20.40 |
| EPS Growth(%) | 64.62 | -27.21 | -50.36 | 87.51 | 20.32 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.21 | 0.18 | 0.10 | 0.23 | 0.33 |
| Current Ratio(x) | 1.95 | 1.87 | 2.21 | 1.85 | 1.44 |
| Quick Ratio(x) | 1.14 | 1.13 | 1.29 | 1.00 | 0.77 |
| Interest Cover(x) | 16.12 | 19.60 | 70.34 | 99.58 | 13.27 |
| Total Debt/Mcap(x) | 0.10 | 0.16 | 0.06 | 0.10 | 0.23 |
Compare Financial Ratios of peers of AUROBINDO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AUROBINDO PHARMA | ₹72,059.9 Cr | -0.4% | 1.7% | 22.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
| CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics | |
AUROBINDO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AUROBINDO PHARMA | -0.4% |
1.7% |
22.9% |
| SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses
